Stallergenes
 | |
| Type | Public (Euronext: GENP) |
|---|---|
| Industry | Biopharmaceuticals |
| Founded | 1962[1] |
| Headquarters | Antony, Hauts-de-Seine, France |
| Key people | Roberto Gradnik (Chief Executive Officer) |
| Revenue |
 €240 million |
Stallergenes is a European biopharmaceutical company specialized in the manufacture of immunotherapy medicines for the prevention and treatment of allergic respiratory diseases such as rhinoconjunctivitis and allergic asthma. It is Europe’s second largest maker of allergy medicines,[2][3] conducts 85% of its business in Europe,[4] and is the 7th largest French pharmaceutical firm. A world leader in sublingual immunotherapy, the group is present in 18 countries and distributes its products in about 50 countries via numerous partnerships and distribution agreements.[5] In 2012, the Group's turnover amounted to € 240M.
Corporate history
Stallergenes was created in Lyon, France in 1962, within the Institut Mérieux. By 1974 the company had expanded its operations into the Benelux countries and North Africa. By the late 1980s, Stallergenes had developed and supplied some of the world's first orally administered anti-allergies vaccines.[2] In 1989, Stallergenes and Institut Pasteur merged their manufacturing activities and begin a joint research programme on allergens. In 1998 it became a publicly listed company, and in 1999 it purchased DHS, Bayer Schering Pharmas allergy division, to become the world’s "number 2" company in its specialist field.[2]
In 2010, Stallergenes signed an exclusive partnership agreement with Japanese biopharmaceutical company Shionogi & Co., Ltd. to promote the development, registration, and distribution of the "Stalair Program" in Japan. Sublingual allergen immunotherapy is not currently available in Japan, which has some 32 million sufferers of allergic respiratory diseases.[6] House dust mites and Japanese cedar pollen are the two main causes of respiratory allergies and the Japanese cedar allergy is a major public health concern in the country.[6] Allergic rhinitis affects 25%[7] of the population in Japan, and asthma 6.7%.[8]
Stock market information
Company listed on the second marché of the Paris stock exchange since 1998
Share capital ownership at 31 December 2012:
- Ares Life Sciences: 75.5%
- Float: 21.5%
- Management & employees: 2.8%
- Free Float: 0.2%
Executive committee
- Roberto GRADNIK: Chief Executive Officer
- Peter BUHLER: Chief Financial Officer
- Olivier de BEAUMONT: Senior VP, Global Medical Affairs
- Cécile HILAIRE: Senior VP, Strategic Marketing and Market Access
- Robert ZELDIN: Senior VP, Global Clinical Development
- Thomas LANG: Senior VP, General Manager US
- Richard LEJOSNE: Senior VP, Human Resources
- Philippe MOINGEON: Senior VP, Research and Pharmaceutical Development
- Cyril TAVIER: Senior VP, Southern Europe Operations
- Poul SORENSEN: Senior VP, Strategic Development
- Pierre CATIGNOL: Senior VP, Industrial Operations & Supply Chain
A pharmaceutical and clinical development programme
Stalair is the pharmaceutical and clinical development programme for immunotherapy tablets being implemented by Stallergenes with a view to obtaining marketing authorisations for pharmaceutical products in Europe and on other strategic markets. Launched in 2003 in line with the European Medicines Agency directives issued in 2009, the programme gives immunotherapy tablets the same level of recognition as standard pharmaceutical products.
- Oralair is the first product originating from this programme. Today, Oralair® is marketed in 21 European countries: France, Canada, Germany, Austria, Belgium, Bulgaria, Spain, Ireland, Italy, the Netherlands, Poland, the Czech Republic, Romania, Slovakia, Slovenia, Lithuania, Latvia, Switzerland, as well as in Australia and New Zealand.
Oralair® is the first immunotherapy tablet registered on the North American continent.
- The second project in this programme is the house dust mites immunotherapy tablet.
Altogether, the pharmaceutical and clinical development programme covers 80% of the epidemiology in all markets.
References
- ↑ "Linked In: Stallergenes".
- ↑ 2.0 2.1 2.2 "2004 Stallergenes Annual Business Report".
- ↑ "Stallergenes to Seek U.S. Partner After FDA Meeting".
- ↑ "Presseportal: Stallergenes".
- ↑ "Stallergenes 2009 Financial Report".
- ↑ 6.0 6.1 "Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan".
- ↑ Sakurai Y, Nakamura K, Teruya K, Shimada N, Umeda T, Tanaka H, Yoshizawa N. Prevalence and risk factors of allergic rhinitis and cedar pollinosis among Japanese men. Prev Med. 1998 Jul-Aug;27(4):617-22.
- ↑ Masoli M, Fabian D, Holt S, Beasley R; Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004 May;59 (5):469-78.
External links